The
Eph receptor tyrosine kinases and their membrane-bound
ephrin ligands form a unique cell-cell contact-mediated system for controlling cell localization and organization. Their high expression in a wide variety of human
tumors indicates a role in
tumor progression, and relatively low Eph and
ephrin levels in normal tissues make these
proteins potential targets for anticancer
therapies. The
monoclonal antibody IIIA4, previously used to isolate EphA3, binds with subnanomolar affinity to a conformation-specific
epitope within the
ephrin-binding domain that is closely adjacent to the "low-affinity"
ephrin-A5 heterotetramerization site. We show that similar to
ephrin-A5, preclustered IIIA4 effectively triggers EphA3 activation, contraction of the cytoskeleton, and cell rounding. BIAcore analysis, immunoblot, and confocal microscopy of wild-type and mutant EphA3 with compromised
ephrin-A5 or IIIA4-binding capacities indicate that IIIA4 binding triggers an EphA3 conformation which is permissive for the assembly of EphA3/
ephrin-A5-type signaling clusters. Furthermore, unclustered IIIA4 and
ephrin-A5 Fc applied in combination initiate greatly enhanced EphA3 signaling. Radiometal conjugates of
ephrin-A5 and IIIA4 retain their affinity, and in mouse xenografts localize to, and are internalized rapidly into EphA3-positive, human
tumors. These findings show the
biological importance of EphA3/
ephrin-A5 interactions and that
ephrin-A5 and IIIA4 have great potential as
tumor targeting
reagents.